MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
175.96%
Quick Ratio
175.96%
Cash Ratio
58.15%
Debt to Asset Ratio
67.14%
Unit: Dollar
Assets Breakdown
    • Investments
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
    • Intangible assets, net
Liabilities Breakdown
    • Additional paid in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
3,845,606
3,124,523
3,818,096
1,830,906
Investments
6,954,476
10,918,778
14,927,165
3,581,772
Prepaid expenses and other current assets
836,146
1,291,256
1,261,974
602,652
Total current assets
11,636,228
15,334,557
20,007,235
6,015,330
Intangible assets, net
333,334
358,334
383,334
408,334
Total assets
11,969,562
15,692,891
20,390,569
6,423,664
Accounts payable
3,109,517
1,776,231
1,262,222
1,860,719
Accrued expenses
1,757,390
1,823,544
2,538,457
2,157,581
Accrued interest and financing expense
1,146,251
1,146,251
1,146,251
1,146,251
Due to officers - short term
600,000
600,000
600,000
600,000
Total current liabilities
6,613,158
5,346,026
5,546,930
5,764,551
Due to officers - long term
1,423,733
1,573,733
1,723,733
1,873,733
Total liabilities
8,036,891
6,919,759
7,270,663
7,638,284
Ordinary shares, no par value per share, 5,000,000,000 authorized at june 30, 2026 and december 31, 2025, respectively - 70,294,615 (2,008,418 ads's) ordinary shares issued and outstanding at june 30, 2026 and 52,441,360 (1,498,325 ads's) ordinary shares issued and outstanding at december 31, 2025
0
0
0
0
Accumulated other comprehensive loss
-582
-159
-613
-
Additional paid in capital
85,272,477
84,741,473
84,090,966
65,407,454
Accumulated deficit
-81,339,224
-75,968,182
-70,970,447
-66,622,074
Total shareholders' equity
3,932,671
8,773,132
13,119,906
-1,214,620
Total liabilities and shareholders' equity
11,969,562
15,692,891
20,390,569
6,423,664
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Investments$6,954,476 (13.60%↑ Y/Y)Cash and cashequivalents$3,845,606 (130.48%↑ Y/Y)Prepaid expenses andother current assets$836,146 (21.37%↑ Y/Y)Total current assets$11,636,228 (37.23%↑ Y/Y)Intangible assets, net$333,334 (-23.08%↓ Y/Y)Total assets$11,969,562 (34.30%↑ Y/Y)Total liabilities andshareholders' equity$11,969,562 (34.30%↑ Y/Y)Total liabilities$8,036,891 (26.34%↑ Y/Y)Total shareholders'equity$3,932,671 (54.14%↑ Y/Y)Accumulated deficit-$81,339,224 (-29.78%↓ Y/Y)Accumulated othercomprehensive loss-$582 Total currentliabilities$6,613,158 (52.46%↑ Y/Y)Due to officers -long term$1,423,733 (-29.65%↓ Y/Y)Additional paid in capital$85,272,477 (30.74%↑ Y/Y)Accounts payable$3,109,517 (255.91%↑ Y/Y)Accrued expenses$1,757,390 (2.32%↑ Y/Y)Accrued interest andfinancing expense$1,146,251 (0.00%↑ Y/Y)Due to officers -short term$600,000 (200.00%↑ Y/Y)

Quoin Pharmaceuticals, Ltd. (QNRX)

Quoin Pharmaceuticals, Ltd. (QNRX)